

# Silvio Danese

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1120660/publications.pdf>

Version: 2024-02-01

727  
papers

42,720  
citations

3334

91  
h-index

3486

182  
g-index

748  
all docs

748  
docs citations

748  
times ranked

27440  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2013, 369, 699-710.	27.0	2,114
2	Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. <i>American Journal of Gastroenterology</i> , 2015, 110, 1324-1338.	0.4	1,425
3	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 28-62.	1.3	1,247
4	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2017, 376, 1723-1736.	27.0	1,232
5	STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. <i>Gastroenterology</i> , 2021, 160, 1570-1583.	1.3	1,054
6	Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2011, 365, 1713-1725.	27.0	982
7	Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis. <i>Gastroenterology</i> , 2014, 146, 392-400.e3.	1.3	778
8	Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. <i>Lancet, The</i> , 2016, 388, 1281-1290.	13.7	771
9	Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2019, 381, 1201-1214.	27.0	703
10	Ulcerative colitis. <i>Nature Reviews Disease Primers</i> , 2020, 6, 74.	30.5	678
11	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2017, 390, 2779-2789.	13.7	633
12	The safety of vedolizumab for ulcerative colitis and Crohn's disease. <i>Gut</i> , 2017, 66, 839-851.	12.1	630
13	Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. <i>Gut</i> , 2011, 60, 463-472.	12.1	612
14	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 135-149.	1.3	558
15	Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESCAR evidence-based consensus guidelines. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 556-585.	1.3	541
16	Development of the Crohn's disease digestive damage score, the Lönnemann score. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1415-1422.	1.9	496
17	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2019, 381, 1215-1226.	27.0	457
18	Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1663-1672.	4.4	437

#	ARTICLE	IF	CITATIONS
19	European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 211-222.	1.3	425
20	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 1-33.	1.3	422
21	Crohn's disease. <i>Nature Reviews Disease Primers</i> , 2020, 6, 22.	30.5	420
22	Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. <i>Gastroenterology</i> , 2019, 157, 647-659.e4.	1.3	393
23	Angiogenesis as a Novel Component of Inflammatory Bowel Disease Pathogenesis. <i>Gastroenterology</i> , 2006, 130, 2060-2073.	1.3	339
24	Application of Artificial Intelligence to Gastroenterology and Hepatology. <i>Gastroenterology</i> , 2020, 158, 76-94.e2.	1.3	335
25	Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1334-1342.e4.	1.3	331
26	Inflammation and Coagulation in Inflammatory Bowel Disease: The Clot Thickens. <i>American Journal of Gastroenterology</i> , 2007, 102, 174-186.	0.4	322
27	Development and validation of the Nancy histological index for UC. <i>Gut</i> , 2017, 66, 43-49.	12.1	322
28	Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 30-35.	4.4	316
29	Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 477-483.	1.3	310
30	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 348-354.e17.	4.4	309
31	Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1385-1397.e10.	4.4	303
32	New therapies for inflammatory bowel disease: from the bench to the bedside. <i>Gut</i> , 2012, 61, 918-932.	12.1	283
33	Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. <i>Gut</i> , 2020, 69, 1213-1217.	12.1	283
34	Biologic agents for IBD: practical insights. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 537-545.	17.8	257
35	Development of the Lönnemann Index to Assess Digestive Tract Damage in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2015, 148, 52-63.e3.	1.3	257
36	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , 2016, 150, 1568-1578.	1.3	251

#	ARTICLE	IF	CITATIONS
37	Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2021, 385, 1280-1291.	27.0	243
38	Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. <i>Gastroenterology</i> , 2017, 153, 77-86.e6.	1.3	232
39	Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. <i>Gut</i> , 2014, 63, 433-441.	12.1	222
40	Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. <i>Gut</i> , 2013, 62, 1556-1565.	12.1	221
41	Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. <i>Gut</i> , 2018, 67, 53-60.	12.1	203
42	Mesenchymal Stem Cells Reduce Colitis in Mice via Release of TSG6, Independently of Their Localization to the Intestine. <i>Gastroenterology</i> , 2015, 149, 163-176.e20.	1.3	201
43	ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 26-34.	1.3	194
44	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2021, 397, 2372-2384.	13.7	194
45	Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 158, 1554-1573.e12.	1.3	189
46	VEGF-Dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. <i>Journal of Clinical Investigation</i> , 2014, 124, 3863-3878.	8.2	183
47	Biological Agents for Moderately to Severely Active Ulcerative Colitis. <i>Annals of Internal Medicine</i> , 2014, 160, 704.	3.9	178
48	Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 158, 562-572.e12.	1.3	173
49	ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). <i>Journal of Crohn's and Colitis</i> , 2013, 7, 586-589.	1.3	169
50	Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. <i>Drugs</i> , 2018, 78, 463-478.	10.9	169
51	Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 229-239.e5.	4.4	164
52	Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study*. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1042-1047.	1.9	160
53	IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. <i>Nature Communications</i> , 2018, 9, 2427.	12.8	159
54	Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2017, 390, 135-144.	13.7	157

#	ARTICLE	IF	CITATIONS
55	Validation of Endoscopic Activity Scores in Patients With Crohn's Disease Based on a Post Hoc Analysis of Data From SONIC. <i>Gastroenterology</i> , 2013, 145, 978-986.e5.	1.3	155
56	IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. <i>Gut</i> , 2016, 65, 1447-1455.	12.1	155
57	Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1548.	2.4	147
58	Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF- $\hat{\pm}$ agents. <i>Autoimmunity Reviews</i> , 2014, 13, 15-19.	5.8	145
59	Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 1007-1018.e7.	1.3	145
60	Long-term Efficacy of Vedolizumab for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw176.	1.3	141
61	Comparing histological activity indexes in UC. <i>Gut</i> , 2015, 64, 1412-1418.	12.1	140
62	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw177.	1.3	140
63	Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 139-147.	4.4	138
64	Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. <i>Gut</i> , 2015, 64, 243-249.	12.1	137
65	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2524.	7.4	136
66	Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1068-1076.	3.7	132
67	Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). <i>Gut</i> , 2019, 68, 40-48.	12.1	132
68	Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 161-170.	8.1	131
69	Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 921-929.	1.3	130
70	JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G155-G162.	3.4	126
71	Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 125-135.	1.5	126
72	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. <i>Gastroenterology</i> , 2020, 159, 139-147.	1.3	126

#	ARTICLE	IF	CITATIONS
73	Colonic diverticular disease. <i>Nature Reviews Disease Primers</i> , 2020, 6, 20.	30.5	125
74	Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease - a double-blind, randomised, placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 741-751.	3.7	123
75	Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 454-465.	3.7	123
76	Next generation of small molecules in inflammatory bowel disease. <i>Gut</i> , 2017, 66, 199-209.	12.1	122
77	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. <i>Gastroenterology</i> , 2021, 160, 2435-2450.e34.	1.3	118
78	The PROSIT-BIO Cohort. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 233-243.	1.9	116
79	Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018, 154, 1320-1333.e10.	1.3	116
80	Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 838-846.e2.	4.4	116
81	Vascular Endothelial Growth Factor C Disrupts the Endothelial Lymphatic Barrier to Promote Colorectal Cancer Invasion. <i>Gastroenterology</i> , 2015, 148, 1438-1451.e8.	1.3	114
82	Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 380-388.e4.	1.3	114
83	Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. <i>Journal of Autoimmunity</i> , 2017, 80, 10-27.	6.5	114
84	Comorbidities in inflammatory bowel disease: a call for action. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 643-654.	8.1	112
85	Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF- $\alpha$ therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1-10.	3.7	110
86	Colorectal cancer in inflammatory bowel disease: Results of the 3rd ECCO pathogenesis scientific workshop (I). <i>Journal of Crohn's and Colitis</i> , 2014, 8, 5-18.	1.3	110
87	Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. <i>Clinical and Experimental Immunology</i> , 2013, 173, 250-258.	2.6	109
88	Development of an index to define overall disease severity in IBD. <i>Gut</i> , 2018, 67, 244-254.	12.1	108
89	Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 14-23.	4.4	108
90	Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 415-433.	8.0	106

#	ARTICLE	IF	CITATIONS
91	Big data in IBD: a look into the future. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 312-321.	17.8	103
92	Management of IBD during the COVID-19 outbreak: resetting clinical priorities. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 253-255.	17.8	103
93	Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 664-684.	3.7	102
94	Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2134-2135.	4.4	101
95	Programming of Intestinal Epithelial Differentiation by IL-33 Derived from Pericryptal Fibroblasts in Response to Systemic Infection. <i>Cell Reports</i> , 2016, 15, 1743-1756.	6.4	100
96	JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?. <i>Gut</i> , 2019, 68, 1893-1899.	12.1	100
97	ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1503-1511.	1.3	100
98	Evolving therapeutic goals in ulcerative colitis: towards disease clearance. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 1-2.	17.8	97
99	Long-term safety of vedolizumab for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1353-1365.	3.7	97
100	Review Article: Inherited Thrombophilia in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2003, 98, 1247-1251.	0.4	95
101	Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1548-1550.	1.3	95
102	Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 819-828.	8.1	95
103	Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process. <i>American Journal of Gastroenterology</i> , 2012, 107, 1770-1776.	0.4	93
104	Review article: the role of anti-TNF in the management of ulcerative colitis – past, present and future. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 855-866.	3.7	90
105	Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 2677-2682.	0.4	88
106	Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1362-1365.	1.3	88
107	Novel therapeutic targets for inflammatory bowel disease. <i>Journal of Autoimmunity</i> , 2017, 85, 103-116.	6.5	88
108	Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. <i>Gastroenterology</i> , 2022, 162, 1650-1664.e8.	1.3	88

#	ARTICLE	IF	CITATIONS
109	Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations: Table 1.. Journal of Crohn's and Colitis, 2017, 11, 128-133.	1.3	87
110	Development of Drugs to Target Interactions Between Leukocytes and Endothelial Cells and Treatment Algorithms for Inflammatory Bowel Diseases. Gastroenterology, 2014, 147, 981-989.	1.3	85
111	Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. Journal of Crohn's and Colitis, 2018, 12, 1385-1391.	1.3	85
112	Intestinal myofibroblast-specific Tpl2-Cox-2-PGE <sub>2</sub> pathway links innate sensing to epithelial homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4658-67.	7.1	83
113	Early intervention in Crohn's disease: towards disease modification trials. Gut, 2017, 66, 2179-2187.	12.1	83
114	Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce. Journal of Crohn's and Colitis, 2020, 14, S798-S806.	1.3	83
115	Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. Journal of Crohn's and Colitis, 2015, 9, 601-606.	1.3	81
116	Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 1179-1192.	3.7	81
117	Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. Journal of Crohn's and Colitis, 2018, 12, 1280-1287.	1.3	79
118	Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. The Lancet Gastroenterology and Hepatology, 2020, 5, 598-606.	8.1	79
119	Biosimilars in IBD: from theory to practice. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 22-31.	17.8	77
120	Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. Journal of Crohn's and Colitis, 2018, 12, 621-626.	1.3	77
121	NKp46-expressing human gut-resident intraepithelial V $\gamma$ 1 T cell subpopulation exhibits high antitumor activity against colorectal cancer. JCI Insight, 2019, 4, .	5.0	77
122	The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?. Journal of Crohn's and Colitis, 2018, 12, 105-119.	1.3	76
123	Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease. Medicine (United States), 2016, 95, e2308.	1.0	73
124	Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Alimentary Pharmacology and Therapeutics, 2022, 55, 464-478.	3.7	73
125	Adalimumab in active ulcerative colitis: A "real-life" observational study. Digestive and Liver Disease, 2013, 45, 738-743.	0.9	72
126	Revisiting fibrosis in inflammatory bowel disease: the gut thickens. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 169-184.	17.8	71



#	ARTICLE	IF	CITATIONS
127	JAK inhibition in inflammatory bowel disease. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 693-703.	3.0	70
128	Role of Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 659-668.	1.3	70
129	Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. <i>Gut Microbes</i> , 2019, 10, 149-158.	9.8	70
130	Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1330-1333.	1.3	69
131	Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target. <i>Current Drug Targets</i> , 2013, 14, 1508-1521.	2.1	69
132	Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study. <i>United European Gastroenterology Journal</i> , 2016, 4, 784-793.	3.8	68
133	The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. <i>Autoimmunity Reviews</i> , 2014, 13, 751-755.	5.8	67
134	The nocebo effect: a clinical challenge in the era of biosimilars. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 739-749.	3.0	67
135	Infliximab in Steroid-dependent Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1065-1072.	1.9	66
136	Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 27-38.	1.3	66
137	Bowel Damage as Assessed by the Lönnemann Index is Reversible on Anti-TNF Therapy for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 633-639.	1.3	65
138	Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 271-280.	3.7	65
139	Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S678-S686.	1.3	64
140	Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences. <i>United European Gastroenterology Journal</i> , 2019, 7, 1008-1032.	3.8	64
141	Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9Âmg: pooled analysis of two phase 3 studies. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 409-418.	3.7	63
142	Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. <i>Digestive Diseases</i> , 2019, 37, 266-283.	1.9	63
143	Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 631-632.	8.1	63
144	Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor. <i>EBioMedicine</i> , 2020, 54, 102719.	6.1	62

#	ARTICLE	IF	CITATIONS
145	New therapeutic avenues in ulcerative colitis: thinking out of the box. <i>Gut</i> , 2013, 62, 1642-1652.	12.1	61
146	Review article: the histological assessment of disease activity in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 957-967.	3.7	60
147	Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1055-1065.	3.7	60
148	The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-Integrin therapies. <i>Medicinal Research Reviews</i> , 2020, 40, 245-262.	10.5	60
149	Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2244-2255.e9.	4.4	60
150	Surgical rates in the era of biological therapy. <i>Current Opinion in Gastroenterology</i> , 2017, 33, 246-253.	2.3	59
151	Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 363-378.	3.1	58
152	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. <i>Drugs</i> , 2020, 80, 99-113.	10.9	58
153	Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 595-599.	4.1	57
154	Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 659-667.	8.1	57
155	First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 345-351.	17.8	56
156	Review article: optimal preparation for surgery in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1009-1022.	3.7	56
157	Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481984863.	3.2	56
158	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 857-873.	17.8	56
159	Vedolizumab for the Treatment of IBD: A Selective Therapeutic Approach Targeting Pathogenic a4b7 Cells. <i>Current Drug Targets</i> , 2013, 14, 1433-1443.	2.1	56
160	Anaemia from a patient perspective in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1385-1391.	1.6	55
161	Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1368-1374.	1.9	55
162	TREM-1 Inhibition Restores Impaired Autophagy Activity and Reduces Colitis in Mice. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 230-244.	1.3	55

#	ARTICLE	IF	CITATIONS
163	Review article: faecal calprotectin and histologic remission in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 689-698.	3.7	55
164	Positioning Therapies in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1280-1290.e1.	4.4	54
165	Bacterial Sensor Triggering Receptor Expressed on Myeloid Cells-2 Regulates the Mucosal Inflammatory Response. <i>Gastroenterology</i> , 2013, 144, 346-356.e3.	1.3	53
166	Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. <i>Cancer Research</i> , 2019, 79, 4196-4210.	0.9	53
167	A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies. <i>Scientific Reports</i> , 2019, 9, 2064.	3.3	53
168	Short-Term Outcomes of Laparoscopy Combined with Enhanced Recovery Pathway after Ileocecal Resection for Crohn's Disease: a Case-Matched Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 126-132.	1.7	52
169	Anaemia management in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1456-1463.	1.6	52
170	Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1095-1103.	3.7	52
171	Integrated Models of Care in Managing Inflammatory Bowel Disease: A Discussion. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1582-1587.	1.9	51
172	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 568-579.	1.9	51
173	Inflammatory bowel disease: estimates from the global burden of disease 2017 study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 261-270.	3.7	51
174	Treatment of Perianal Fistulas in Crohn's Disease, Seton Versus Anti-TNF Versus Surgical Closure Following Anti-TNF [PISA]: A Randomised Controlled Trial. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1049-1056.	1.3	51
175	COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2366-2368.e3.	4.4	51
176	Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 601-606.	1.9	50
177	Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure. <i>American Journal of Gastroenterology</i> , 2020, 115, 179-189.	0.4	50
178	Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2689-2700.	4.4	50
179	Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 820-830.	3.7	50
180	Challenges to the Design, Execution, and Analysis of Randomized Controlled Trials for Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2012, 143, 1461-1469.	1.3	49

#	ARTICLE	IF	CITATIONS
181	Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases. <i>Frontiers in Immunology</i> , 2017, 8, 1331.	4.8	49
182	Catching the Therapeutic Window of Opportunity in Early Crohn's Disease. <i>Current Drug Targets</i> , 2014, 15, 1056-1063.	2.1	49
183	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 118-127.	8.1	49
184	MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. <i>Gastroenterology</i> , 2017, 153, 1363-1377.e6.	1.3	48
185	Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2022, 162, 26-31.	1.3	48
186	Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2019, 157, 1032-1043.e1.	1.3	48
187	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2017, 49, 604-617.	0.9	47
188	PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1276.	4.1	47
189	Colorectal cancer prevention in patients with ulcerative colitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 103-109.	2.4	47
190	Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1222-1234.	1.3	47
191	Perception of Reproductive Health in Women with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 886-891.	1.3	46
192	Point-of-Care Ultrasound in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 143-151.	1.3	46
193	Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2526-2534.e9.	4.4	45
194	PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system. <i>Gut</i> , 2022, 71, 889-898.	12.1	45
195	Advances in therapeutic interventions targeting the vascular and lymphatic endothelium in inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 608-613.	2.3	43
196	Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1058-1072.	3.7	43
197	Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2397-2415.	4.4	43
198	The gut virome in inflammatory bowel disease pathogenesis: From metagenomics to novel therapeutic approaches. <i>United European Gastroenterology Journal</i> , 2019, 7, 999-1007.	3.8	43

#	ARTICLE	IF	CITATIONS
199	Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1569-1577.	1.3	43
200	Internet use among inflammatory bowel disease patients: an Italian multicenter survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1036-1041.	1.6	42
201	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017, 49, 338-358.	0.9	42
202	Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1181-1187.	3.7	42
203	The Brain-Gut Axis: Psychological Functioning and Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2021, 10, 377.	2.4	42
204	Calcium supplementation for the prevention of colorectal adenomas: A systematic review and meta-analysis of randomized controlled trials. <i>World Journal of Gastroenterology</i> , 2016, 22, 4594.	3.3	42
205	Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 294-306.	8.1	42
206	Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 366.	1.6	40
207	Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1882-1883.	4.4	40
208	Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1658-1675.	3.7	40
209	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2014, 46, 963-968.	0.9	39
210	The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation. <i>Gut</i> , 2015, 64, 589-600.	12.1	39
211	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1426-1432.e1.	4.4	39
212	Management of gastrointestinal and liver diseases during pregnancy. <i>Gut</i> , 2014, 63, 1014-1023.	12.1	38
213	Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jcw185.	1.3	38
214	Gastroenterology department operational reorganisation at the time of covid-19 outbreak: an Italian and Chinese experience. <i>Gut</i> , 2020, 69, 981-983.	12.1	38
215	The Inflammatory Bowel Disease Transcriptome and Metatranscriptome Meta-Analysis (IBD TaMMA) framework. <i>Nature Computational Science</i> , 2021, 1, 511-515.	8.0	38
216	Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation. <i>Journal of Clinical Investigation</i> , 2016, 126, 611-626.	8.2	38

#	ARTICLE	IF	CITATIONS
217	Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme. <i>Oncotarget</i> , 2014, 5, 3711-3727.	1.8	37
218	The triggering receptor expressed on myeloid cells (TREM) in inflammatory bowel disease pathogenesis. <i>Journal of Translational Medicine</i> , 2014, 12, 293.	4.4	37
219	Dose optimization is effective in ulcerative colitis patients losing response to infliximab: A collaborative multicentre retrospective study. <i>Digestive and Liver Disease</i> , 2014, 46, 135-139.	0.9	37
220	Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 976-985.	1.9	37
221	Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 43-47.	2.4	37
222	Liver tests abnormalities in COVID-19: trick or treat?. <i>Journal of Hepatology</i> , 2020, 73, 1275-1276.	3.7	37
223	Head-to-head trials in inflammatory bowel disease: past, present and future. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 365-376.	17.8	37
224	Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 335-339.	1.3	37
225	Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results. <i>Gastroenterology</i> , 2022, 162, 1876-1890.	1.3	37
226	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019, 51, 632-639.	0.9	36
227	SARS-CoV-2 vaccination in IBD: more pros than cons. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 211-213.	17.8	36
228	Microscopic features of colorectal neoplasia in inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2014, 20, 3164.	3.3	36
229	Breaking Through the Therapeutic Ceiling: What Will It Take?. <i>Gastroenterology</i> , 2022, 162, 1507-1511.	1.3	36
230	Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1317-1325.	1.3	35
231	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". <i>Digestive and Liver Disease</i> , 2017, 49, 17-23.	0.9	35
232	Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 417-423.	1.3	35
233	Drug development in IBD: from novel target identification to early clinical trials. <i>Gut</i> , 2016, 65, 1233-1239.	12.1	34
234	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2016, 48, 360-370.	0.9	34

#	ARTICLE	IF	CITATIONS
235	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. <i>Gastroenterology</i> , 2018, 155, 76-87.	1.3	34
236	Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease. <i>Techniques in Coloproctology</i> , 2020, 24, 421-448.	1.8	34
237	Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy. <i>Autoimmunity Reviews</i> , 2021, 20, 102832.	5.8	34
238	Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. <i>Current Medicinal Chemistry</i> , 2019, 26, 259-269.	2.4	34
239	MRI in Crohn's disease – current and future clinical applications. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 23-31.	17.8	33
240	Comparison Between 1.5 and 3.0 Tesla Magnetic Resonance Enterography for the Assessment of Disease Activity and Complications in Ileo-Colonic Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3246-3255.	2.3	33
241	Effect of Tumor Necrosis Factor- $\alpha$ Blockade on Mucosal Addressin Cell-adhesion Molecule-1 in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 259-264.	1.9	33
242	Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study. <i>United European Gastroenterology Journal</i> , 2016, 4, 604-613.	3.8	33
243	Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. <i>Digestive and Liver Disease</i> , 2017, 49, 872-877.	0.9	33
244	Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 633-641.	4.7	33
245	Use of Cross-Sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1309-1323.e4.	4.4	33
246	TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 840-859.	1.3	33
247	Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 2023-2030.	1.9	33
248	Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1059-1067.e9.	4.4	33
249	Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes. <i>Scientific Reports</i> , 2015, 5, 13647.	3.3	32
250	Haematopoietic prolyl hydroxylase-1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis. <i>Journal of Pathology</i> , 2017, 241, 547-558.	4.5	32
251	Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 239-251.	2.4	32
252	Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 970-975.	1.3	32

#	ARTICLE	IF	CITATIONS
253	FOXP3 <sup>+</sup> T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF. <i>BioMed Research International</i> , 2013, 2013, 1-10.	1.9	31
254	Preoperative Magnetic Resonance Enterography in Predicting Findings and Optimizing Surgical Approach in Crohn's Disease. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 83-91.	1.7	31
255	Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 738-746.	1.3	31
256	Can IL-23 be a good target for ulcerative colitis?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 95-102.	2.4	31
257	Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management. <i>Techniques in Coloproctology</i> , 2020, 24, 105-126.	1.8	31
258	Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn's and Colitis Organization. <i>Gastroenterology</i> , 2020, 159, 14-19.e3.	1.3	31
259	Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy. <i>Gastroenterology</i> , 2020, 158, 2302-2304.	1.3	31
260	A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 152-161.	1.3	31
261	International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. <i>United European Gastroenterology Journal</i> , 2021, 9, 451-460.	3.8	31
262	Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 666-678.	8.1	31
263	Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 835-846.	3.0	30
264	Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents. <i>BioDrugs</i> , 2017, 31, 223-237.	4.6	30
265	Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 316-322.	1.6	30
266	Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e723-e740.	4.4	30
267	Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. <i>United European Gastroenterology Journal</i> , 2019, 7, 1285-1303.	3.8	29
268	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3533.	2.4	29
269	Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 552-555.	1.5	28
270	Prevention and Treatment of Venous Thromboembolism in Patients with IBD. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1204-1213.	1.9	28



#	ARTICLE	IF	CITATIONS
271	Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1096-1102.	1.3	28
272	Review article: treating a "target" for inflammatory bowel disease-associated anaemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 610-617.	3.7	28
273	Improving the quality of surveillance colonoscopy in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 971-983.	8.1	28
274	Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 803-810.	1.9	28
275	Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2324-2332.e6.	4.4	28
276	Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. <i>Gastroenterology</i> , 2022, 162, 1891-1910.	1.3	28
277	Patient and physician views on the quality of care in inflammatory bowel disease: Results from SOLUTION-1, a prospective IG-IBD study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1642-1652.	1.3	27
278	Direct Retrospective Comparison of Adalimumab and Infliximab in Preventing Early Postoperative Endoscopic Recurrence After Ileocaecal Resection for Crohn's Disease: Results from the MULTIPER Database. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 541-547.	1.3	27
279	Preventing disability in inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 865-876.	3.2	27
280	Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1180-1190.	1.3	27
281	Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1399-1407.	1.9	27
282	Early Intervention in Ulcerative Colitis: Ready for Prime Time?. <i>Journal of Clinical Medicine</i> , 2020, 9, 2646.	2.4	27
283	Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1562-1571.	1.9	27
284	<i>Roseburia hominis</i> : a novel guilty player in ulcerative colitis pathogenesis?. <i>Gut</i> , 2014, 63, 1204-1205.	12.1	26
285	Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1673-1679.e1.	4.4	26
286	Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 581-594.	2.8	26
287	Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside. <i>Current Drug Targets</i> , 2013, 14, 1444-1452.	2.1	25
288	Preventing Collateral Damage in Crohn's Disease: The Lönnemann Index. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 495-500.	1.3	25

#	ARTICLE	IF	CITATIONS
289	E-health in inflammatory bowel diseases: More challenges than opportunities?. Digestive and Liver Disease, 2017, 49, 1320-1326.	0.9	25
290	Unmet Needs in IBD: the Case of Fatigue. Clinical Reviews in Allergy and Immunology, 2018, 55, 368-378.	6.5	25
291	Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey. United European Gastroenterology Journal, 2019, 7, 1345-1352.	3.8	25
292	Clinician Education and Adoption of Preventive Measures for COVID-19: A Survey of a Convenience Sample of General Practitioners in Lombardy, Italy. Annals of Internal Medicine, 2020, 173, 405-407.	3.9	25
293	The biosimilar road in inflammatory bowel disease: The right way?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 465-471.	2.4	24
294	The safety of biological pharmacotherapy for the treatment of ulcerative colitis. Expert Opinion on Drug Safety, 2017, 16, 437-443.	2.4	24
295	The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. Alimentary Pharmacology and Therapeutics, 2018, 48, 941-950.	3.7	24
296	Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. Journal of Crohn's and Colitis, 2018, 12, 1021-1029.	1.3	24
297	Modulation of sphingosine-1-phosphate in ulcerative colitis. Expert Opinion on Biological Therapy, 2020, 20, 413-420.	3.1	24
298	The management of iron deficiency in inflammatory bowel disease - an online tool developed by the RAND/UCLA appropriateness method. Alimentary Pharmacology and Therapeutics, 2013, 38, 1109-1118.	3.7	23
299	Proximal collagenous gastroenteritides: Clinical management. A systematic review. Annals of Medicine, 2014, 46, 311-317.	3.8	23
300	Treatments for Crohn's Disease-associated Bowel Damage: A Systematic Review. Clinical Gastroenterology and Hepatology, 2019, 17, 847-856.	4.4	23
301	Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence. Digestive and Liver Disease, 2019, 51, 327-334.	0.9	23
302	Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. Journal of Crohn's and Colitis, 2021, 15, 938-949.	1.3	23
303	Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?. Drugs, 2021, 81, 1859-1879.	10.9	23
304	Ustekinumab in the management of Crohn's disease: Expert opinion. Digestive and Liver Disease, 2018, 50, 653-660.	0.9	22
305	Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review. Journal of Crohn's and Colitis, 2020, 14, 688-693.	1.3	22
306	Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials. United European Gastroenterology Journal, 2020, 8, 1013-1030.	3.8	22

#	ARTICLE	IF	CITATIONS
307	Incidence, Prevalence, and Clinical Epidemiology of Inflammatory Bowel Disease in the Arab World: A Systematic Review and Meta-Analysis. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 123-131.	1.9	22
308	Gut eukaryotic virome in colorectal carcinogenesis: Is that a trigger?. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 16-28.	4.1	22
309	Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 835-844.	1.3	22
310	The Role of Diet and Lifestyle in Early-Onset Colorectal Cancer: A Systematic Review. <i>Cancers</i> , 2021, 13, 5933.	3.7	22
311	Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 1211-1217.	1.5	21
312	Anti-TNF and skin inflammation in IBD: a new paradox in gastroenterology?. <i>Gut</i> , 2014, 63, 533-535.	12.1	21
313	Integrins and adhesion molecules as targets to treat inflammatory bowel disease. <i>Current Opinion in Pharmacology</i> , 2015, 25, 67-71.	3.5	21
314	Endothelial Cell-Immune Cell Interaction in IBD. <i>Digestive Diseases</i> , 2016, 34, 43-50.	1.9	21
315	Diffusion-weighted MRI in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 433-443.	8.1	21
316	OP34 VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S612-S613.	1.3	21
317	Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. <i>Digestive and Liver Disease</i> , 2020, 52, 138-142.	0.9	21
318	Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis. <i>Techniques in Coloproctology</i> , 2020, 24, 397-419.	1.8	21
319	Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1087-1095.	3.7	21
320	Validation of the "Inflammatory Bowel Disease" Distribution, Chronicity, Activity [IBD-DCA] Score™ for Ulcerative Colitis and Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1621-1630.	1.3	21
321	Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). <i>Gastroenterology</i> , 2021, 161, 1156-1167.e3.	1.3	21
322	Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 446-454.	3.7	21
323	ECCO Position on Harmonisation of Crohn's Disease Mucosal Histopathology. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 876-883.	1.3	21
324	Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II): a patient preference randomised trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 617-626.	8.1	21

#	ARTICLE	IF	CITATIONS
325	Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. <i>United European Gastroenterology Journal</i> , 2018, 6, 310-321.	3.8	20
326	Antigenic response to CT-13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 507-522.	3.7	20
327	Biosimilars of adalimumab: the upcoming challenge in IBD. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1023-1030.	3.1	20
328	Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 945-954.	1.9	20
329	PTG-100, an Oral $\text{IL-7}$ Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis. <i>Gastroenterology</i> , 2021, 161, 1853-1864.e10.	1.3	20
330	Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art. <i>Journal of Clinical Medicine</i> , 2022, 11, 939.	2.4	20
331	Disease-related and drug-induced skin manifestations in inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 203-214.	3.0	19
332	Herpes Zoster and Vaccination Strategies in Inflammatory Bowel Diseases: A Practical Guide. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 481-490.	4.4	19
333	Treat to target or "treat to clear" in inflammatory bowel diseases: one step further?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 807-817.	3.0	19
334	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. <i>Angiology</i> , 2020, 71, 689-697.	1.8	19
335	Diagnostic Delay in Crohn's Disease: Time for Red Flags. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3097-3098.	2.3	18
336	Management of patients with inflammatory bowel disease and spondyloarthritis. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1363-1374.	3.1	18
337	Are Surgical Rates Decreasing in the Biological Era In IBD?. <i>Current Drug Targets</i> , 2019, 20, 1356-1362.	2.1	18
338	Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1 $\alpha$ stabiliser, for treatment of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 401-411.	3.7	18
339	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 254-261.	8.1	18
340	Systematic review of pancreatic involvement in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1478-1491.	3.7	18
341	TNF inhibitors restrict T cell activation and cycling via Notch-1 signalling in inflammatory bowel disease. <i>Gut</i> , 2012, 61, 1016-1027.	12.1	17
342	The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 503-512.	3.2	17

#	ARTICLE	IF	CITATIONS
343	JAK inhibitors: Novel developments in management of ulcerative colitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 89-93.	2.4	17
344	Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 304-313.	1.9	17
345	Histological healing: should it be considered as a new outcome for ulcerative colitis?. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 407-412.	3.1	17
346	New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?. <i>Current Opinion in Pharmacology</i> , 2020, 55, 141-150.	3.5	17
347	The day after COVID-19 in IBD: how to go back to "normal". <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 441-443.	17.8	17
348	Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. <i>MAbs</i> , 2021, 13, 1868078.	5.2	17
349	Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the iSupport Therapy "Access to Rapid Treatment (iSTART) approach. <i>Intestinal Research</i> , 2018, 16, 522-528.	2.6	17
350	Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 576-584.	8.1	17
351	The future of drug development for inflammatory bowel disease: the need to ACT (advanced) Tj ETQq1 1 0.784314, rgBT /Overlock 10	12.1	17
352	Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis. <i>Digestive and Liver Disease</i> , 2014, 46, 330-334.	0.9	16
353	IL-23 Blockade for Crohn's disease: next generation of anti-cytokine therapy. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 457-467.	3.0	16
354	Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn's Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm. <i>Gastroenterology</i> , 2017, 152, S155.	1.3	16
355	The impact of biologics in surgical outcomes in ulcerative colitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 79-87.	2.4	16
356	Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 731-738.	3.0	16
357	Lymphatic endothelium contributes to colorectal cancer growth via the soluble matrisome component GDF11. <i>International Journal of Cancer</i> , 2019, 145, 1913-1920.	5.1	16
358	SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 507-516.	17.8	16
359	Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1066-1073.	1.3	16
360	Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2013, 108, S502-S503.	0.4	16

#	ARTICLE	IF	CITATIONS
361	Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 302-310.	3.7	16
362	Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110599.	3.2	16
363	Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2858-2867.e5.	4.4	16
364	Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 1897-1913.	4.3	16
365	Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 773-799.	1.9	15
366	Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1258-1266.	1.3	15
367	Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. <i>Digestion</i> , 2017, 96, 166-172.	2.3	15
368	Thiopurines' Metabolites and Drug Toxicity: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2216.	2.4	15
369	PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 797-806.	3.0	15
370	Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 421-427.	3.1	15
371	Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2021, 44, 645-660.	3.2	15
372	Going Beyond Bacteria: Uncovering the Role of Archaeome and Mycobiome in Inflammatory Bowel Disease. <i>Frontiers in Physiology</i> , 2021, 12, 783295.	2.8	15
373	Ultrasound Elastography in Inflammatory Bowel Diseases: A Systematic Review of Accuracy Compared with Histopathological Assessment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1637-1646.	1.3	15
374	Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. <i>BMC Gastroenterology</i> , 2022, 22, .	2.0	15
375	Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2390-2401.	1.9	14
376	Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting. <i>Journal of Digestive Diseases</i> , 2017, 18, 566-573.	1.5	14
377	Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2106-2112.	1.9	14
378	Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs. <i>Cells</i> , 2019, 8, 817.	4.1	14

#	ARTICLE	IF	CITATIONS
379	Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease â€"AGEDâ€" study. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1361-1369.	1.6	14
380	Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality. <i>Digestive and Liver Disease</i> , 2020, 52, 506-515.	0.9	14
381	Tools for fecal incontinence assessment: lessons for inflammatory bowel disease trials based on a systematic review. <i>United European Gastroenterology Journal</i> , 2020, 8, 886-922.	3.8	14
382	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 106-122.	1.9	14
383	Darvadstrocel for the treatment of patients with perianal fistulas in Crohn's disease. <i>Drugs of Today</i> , 2019, 55, 95.	1.1	14
384	Magnetic Resonance Elastography for Assessing Fibrosis in Patients with Crohn's Disease: A Pilot Study. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4518-4524.	2.3	14
385	Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1338-1347.	1.9	14
386	Is it time to include older adults in inflammatory bowel disease trials? A call for action. <i>The Lancet Healthy Longevity</i> , 2022, 3, e356-e366.	4.6	14
387	Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. <i>Immunotherapy</i> , 2015, 7, 175-190.	2.0	13
388	New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 113-120.	1.5	13
389	OP37 Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S025-S026.	1.3	13
390	Environmental, Nutritional, and Socioeconomic Determinants of IBD Incidence: A Global Ecological Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 323-331.	1.3	13
391	Targeting the gut layers in Crohn's disease: mucosal or transmural healing?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 775-787.	3.0	13
392	JAK selectivity: more precision less troubles. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 789-796.	3.0	13
393	Upadacitinib for Crohn's Disease and Ulcerative Colitis Treatment: Hitting the Selective JAKpot. <i>Gastroenterology</i> , 2021, 160, 1472-1474.	1.3	13
394	Viral infections in inflammatory bowel disease: Tips and tricks for correct management. <i>World Journal of Gastroenterology</i> , 2021, 27, 4276-4297.	3.3	13
395	The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease. <i>Current Pharmaceutical Design</i> , 2018, 23, 6759-6769.	1.9	13
396	The prophylactic use of endoscopic vacuum therapy for anastomotic dehiscence after rectal anterior resection: is it feasible for redo surgery?. <i>Techniques in Coloproctology</i> , 2022, 26, 319-320.	1.8	13

#	ARTICLE	IF	CITATIONS
397	Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 265-272.	3.7	13
398	Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 840-842.	3.7	12
399	Preventing Diverticulitis Recurrence by Selecting the Right Therapy for a Complex Disease. <i>Gastroenterology</i> , 2014, 147, 733-736.	1.3	12
400	Biosimilars – terms of use. <i>Current Medical Research and Opinion</i> , 2015, 31, 2325-2330.	1.9	12
401	Clinical development of biologicals and biosimilars - safety concerns. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 567-569.	3.1	12
402	Filgotinib in Crohn's Disease: JAK Is Back. <i>Gastroenterology</i> , 2017, 153, 603-605.	1.3	12
403	mTOR-Dependent Stimulation of IL20RA Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohn's Disease. <i>Cells</i> , 2019, 8, 924.	4.1	12
404	Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-9.	1.5	12
405	OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn's disease: long-term data from CALM. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S024-S025.	1.3	12
406	DOP48 Amiselimod, a selective S1P receptor modulator in Crohn's disease patients: a proof-of-concept study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S055-S056.	1.3	12
407	Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2567-2576.e9.	4.4	12
408	Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next?. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 47-55.	3.1	12
409	Histological Disease Activity Measured by the Nancy Index Is Associated with Long-term Outcomes in Patients with Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1631-1640.	1.3	12
410	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102849.	5.8	12
411	Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , 2020, 9, 1536.	2.4	12
412	Endoscopic vacuum therapy for post-esophagectomy anastomotic dehiscence as rescue treatment: a single center case series. <i>Esophagus</i> , 2022, 19, 417-425.	1.9	12
413	Adalimumab in ulcerative colitis: Ready for prime time. <i>Digestive and Liver Disease</i> , 2013, 45, 8-13.	0.9	11
414	Ustekinumab for treating ulcerative colitis: an expert opinion. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1321-1329.	3.1	11



#	ARTICLE	IF	CITATIONS
415	Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2905.	2.4	11
416	Which MRI Score and Technique Should Be Used for Assessing Crohn's Disease Activity?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1691.	2.4	11
417	Challenges and Opportunities in IBD Clinical Trial Design. <i>Gastroenterology</i> , 2021, 161, 400-404.	1.3	11
418	Incidence of and Risk Factors for Colorectal Strictures in Ulcerative Colitis: A Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1899-1905.e1.	4.4	11
419	Rediscovering histology: what is new in endoscopy for inflammatory bowel disease?. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110056.	3.2	11
420	Targeting lymphatics in inflammatory bowel disease. <i>Oncotarget</i> , 2015, 6, 34047-34048.	1.8	11
421	Imaging Modalities for Perianal Crohn's Disease. <i>Current Drug Targets</i> , 2012, 13, 1287-1293.	2.1	11
422	Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 765-773.	3.0	11
423	OP24 Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn's Disease: Week 48 analyses from the phase 2 GALAXI 1 study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i026-i027.	1.3	11
424	Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm. <i>Journal of Crohn's and Colitis</i> , 2022, 16, ii30-ii41.	1.3	11
425	Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e126.	2.5	10
426	Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 687-694.	1.3	10
427	Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 17-25.	2.4	10
428	Safety of vedolizumab in liver transplant recipients: A systematic review. <i>United European Gastroenterology Journal</i> , 2019, 7, 875-880.	3.8	10
429	Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2244-2254.	2.4	10
430	A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. <i>Cells</i> , 2019, 8, 523.	4.1	10
431	Statins and inflammatory bowel disease: Where do we stand?. <i>European Journal of Internal Medicine</i> , 2020, 75, 10-14.	2.2	10
432	Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan. <i>Pharmacological Research</i> , 2020, 160, 105061.	7.1	10

#	ARTICLE	IF	CITATIONS
433	Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery. <i>Journal of Clinical Medicine</i> , 2020, 9, 2115.	2.4	10
434	OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn's disease: Results of the VISIBLE 2 study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S020-S021.	1.3	10
435	Medical therapy versus surgery in moderate-to-severe ulcerative colitis. <i>Digestive and Liver Disease</i> , 2021, 53, 403-408.	0.9	10
436	Long-term safety of approved biologics for ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 807-816.	2.4	10
437	Thrombosis in IBD in the Era of JAK Inhibition. <i>Current Drug Targets</i> , 2020, 22, 126-136.	2.1	10
438	Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. <i>Advances in Therapy</i> , 2022, 39, 2342-2364.	2.9	10
439	Cross-Sectional Imaging Modalities in Crohn's Disease. <i>Digestive Diseases</i> , 2013, 31, 199-201.	1.9	9
440	Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 885-895.	3.0	9
441	In the Presence of Conceptual Heterogeneity, Results of Network Meta-analysis Comparing Therapies in Crohn's Disease Need to Be Interpreted With Caution. <i>Gastroenterology</i> , 2015, 148, 1483-1484.	1.3	9
442	Urokinase Receptor Promotes Skin Tumor Formation by Preventing Epithelial Cell Activation of Notch1. <i>Cancer Research</i> , 2015, 75, 4895-4909.	0.9	9
443	A multicentre prospective cohort study assessing the effectiveness of budesonide MMX <sup>®</sup> (Cortiment <sup>®</sup> MMX <sup>®</sup> ) for active, mild-to-moderate ulcerative colitis. <i>United European Gastroenterology Journal</i> , 2019, 7, 1171-1182.	3.8	9
444	Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?. <i>Current Pharmaceutical Design</i> , 2019, 25, 25-31.	1.9	9
445	The Role of Pro-Resolving Lipid Mediators in Colorectal Cancer-Associated Inflammation: Implications for Therapeutic Strategies. <i>Cancers</i> , 2020, 12, 2060.	3.7	9
446	Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience. <i>Journal of Clinical Medicine</i> , 2020, 9, 2697.	2.4	9
447	Impact of therapies on bowel damage in Crohn's disease. <i>United European Gastroenterology Journal</i> , 2020, 8, 410-417.	3.8	9
448	Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 37-46.	3.1	9
449	Ethnic Differences in the Smoking-related Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1658-1678.	1.3	9
450	Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know. <i>Digestive and Liver Disease</i> , 2021, 53, 691-696.	0.9	9

#	ARTICLE	IF	CITATIONS
451	Defining difficult-to-treat inflammatory bowel disease: why and how. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 520-522.	8.1	9
452	Prognostic performance of the â€˜DICAâ€™ endoscopic classification and the â€˜CODAâ€™ score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study. <i>Gut</i> , 2022, 71, 1350-1358.	12.1	9
453	Diversion proctocolitis and the problem of the forgotten rectum in inflammatory bowel diseases: A systematic review. <i>United European Gastroenterology Journal</i> , 2021, 9, 1157-1167.	3.8	9
454	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2619-2627.e1.	4.4	9
455	Mucosal healingâ€™EXTENDING our knowledge in Crohn's disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 309-311.	17.8	8
456	Stopping infliximab in crohn's disease: Still an ongoing STORI. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2201-2202.	1.9	8
457	Enriching the therapeutic armamentarium for IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 84-86.	17.8	8
458	Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond?. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1257-1258.	1.3	8
459	To switch or not to switch: that is the biosimilar question. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 508-509.	17.8	8
460	OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn's disease: final results from the GEMINI LTS study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S018-S020.	1.3	8
461	The trend of C-Reactive protein allows a safe early discharge after surgery for Crohn's disease. <i>Updates in Surgery</i> , 2020, 72, 985-989.	2.0	8
462	Challenges and opportunities for IBD drug development: from early stage to regulatory approval. <i>Gut</i> , 2020, 69, 1157-1161.	12.1	8
463	Emerging therapies for the treatment of ulcerative colitis. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 71-79.	2.4	8
464	Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 551-566.	1.3	8
465	Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1037-1046.	4.1	8
466	Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?. <i>Current Pharmaceutical Design</i> , 2019, 25, 7-12.	1.9	8
467	Bowel Damage Assessment in Crohn's Disease by Magnetic Resonance Imaging. <i>Current Drug Targets</i> , 2012, 13, 1300-1307.	2.1	8
468	OP04 Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i004-i005.	1.3	8

#	ARTICLE	IF	CITATIONS
469	Lactobacillus paracasei CNCM I 1572: A Promising Candidate for Management of Colonic Diverticular Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 1916.	2.4	8
470	Editorial [Hot Topic: Ulcerative Colitis: A Cinderella Story (Guest Editor: Silvio Danese)]. <i>Current Drug Targets</i> , 2011, 12, 1372-1372.	2.1	7
471	Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial. <i>American Journal of Gastroenterology</i> , 2012, 107, S609-S610.	0.4	7
472	Golimumab in ulcerative colitis: a 'mÃ©nage Ã trois' of drugs. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 511-512.	17.8	7
473	OP011 Tralokinumab (CAT-354), an interleukin 13 antibody, in moderate to severe ulcerative colitis: A phase 2 randomized placebo-controlled study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S7-S8.	1.3	7
474	Commentary: anaemia in inflammatory bowel disease â€” the most common and ignored extra intestinal manifestation. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 227-228.	3.7	7
475	EMA response to ECCO position statement on biosimilars. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 259.	1.3	7
476	Indirect Treatment Comparison of Ustekinumab Versus Other Biologics In Moderate To Severe Crohnâ€™s Disease: A 1-Year Treatment Sequence Analysis. <i>Value in Health</i> , 2016, 19, A576.	0.3	7
477	Are We Ready to Abandon Placebo in Randomised Clinical Trials for Inflammatory Bowel Disease? Pros and Cons. <i>Journal of Crohn's and Colitis</i> , 2016, 10, S548-S552.	1.3	7
478	Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000092.	2.7	7
479	Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study. <i>Gastroenterology</i> , 2017, 152, S602.	1.3	7
480	Letter: immunogenicity of infliximab originator vs. <scp>CT</scp>â€™P13 in <scp>IBD</scp> patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 903-905.	3.7	7
481	Editorial: tofacitinib and biologics for moderateâ€™toâ€™severe ulcerative colitisâ€™”what is best in class? Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 540-541.	3.7	7
482	Physiciansâ€™ perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (<scp>IOIBD</scp>) survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 773-783.	3.7	7
483	Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 151-161.	3.1	7
484	Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1019-1028.	3.0	7
485	Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S815-S819.	1.3	7
486	The Evolution of Biologics Administration From Intravenous to Subcutaneous: Treatments for Inflammatory Bowel Disease Go Home. <i>Gastroenterology</i> , 2021, 160, 2244-2247.	1.3	7

#	ARTICLE	IF	CITATIONS
487	Anti-TNF and Postoperative Complications in Abdominal Crohn's Disease Surgery. <i>Current Drug Targets</i> , 2019, 20, 1339-1348.	2.1	7
488	Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases. <i>British Medical Bulletin</i> , 2020, 136, 107-117.	6.9	7
489	Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement. <i>BMC Psychology</i> , 2021, 9, 186.	2.1	7
490	DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i090-i091.	1.3	7
491	Review article: randomised controlled trials in inflammatory bowel disease—common challenges and potential solutions. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 658-669.	3.7	7
492	Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 743-744.	3.7	6
493	Adalimumab for the treatment of pediatric Crohn's disease. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 963-972.	3.0	6
494	764 Results of Andante, a Randomized Clinical Study With an Anti-IL6 Antibody (PF-04236921) in Subjects With Crohn's Disease Who Are Anti-TNF Inadequate Responders. <i>Gastroenterology</i> , 2016, 150, S155.	1.3	6
495	Emerging therapeutic targets and strategies in Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 735-744.	3.0	6
496	Vedolizumab for the treatment of Crohn's disease. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 179-189.	3.0	6
497	Infliximab biosimilar CT-P13 for inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 373-375.	8.1	6
498	DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S061-S062.	1.3	6
499	Is there a role for therapeutic sphingolipids in inflammatory bowel disease?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 47-54.	3.0	6
500	Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 710-718.	1.3	6
501	Tofacitinib for Acute Severe Colitis: When the going Gets Tough, the Tough Get Going. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 883-885.	1.3	6
502	Efficacy of anti-TNF drugs in patients with stricturing Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 347-353.	3.0	6
503	Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile. <i>Current Medicinal Chemistry</i> , 2019, 26, 280-287.	2.4	6
504	P495 Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i460-i460.	1.3	6

#	ARTICLE	IF	CITATIONS
505	Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. <i>Biomedicines</i> , 2022, 10, 843.	3.2	6
506	Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 390-391.	8.1	6
507	The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis. <i>Journal of Multidisciplinary Healthcare</i> , 2022, Volume 15, 815-824.	2.7	6
508	Early Biological Therapy in Operated Crohn's Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 539-547.	1.9	6
509	Mesenchymal stromal cells in inflammatory bowel disease: conspirators within the "colitogenic niche"? <i>Gut</i> , 2013, 62, 1098-1099.	12.1	5
510	Reductions in Corticosteroid Use in Patients with Ulcerative Colitis or Crohn's Disease Treated with Vedolizumab. <i>American Journal of Gastroenterology</i> , 2013, 108, S503.	0.4	5
511	439 The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilar. <i>Gastroenterology</i> , 2016, 150, S92.	1.3	5
512	Biosimilar therapies in inflammatory bowel disease: should we care about patient profile?. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 361-363.	3.0	5
513	DOP50 Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn's disease: data from the CELEST study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S057-S057.	1.3	5
514	Time to include patients with ulcerative proctitis in clinical trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 900-902.	8.1	5
515	Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 353-361.	3.1	5
516	Transmural Histological Scoring Systems in Crohn's Disease: A Systematic Review With Assessment of Methodological Quality and Operating Properties. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 743-756.	1.3	5
517	OP15 A new simplified histology artificial intelligence system for accurate assessment of remission in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i015-i017.	1.3	5
518	Inflammatory bowel diseases and psychological issues: A new approach for a systematic analysis of the academic debate. <i>Psychology, Health and Medicine</i> , 2014, 19, 559-571.	2.4	4
519	Anemia in Inflammatory Bowel Disease: The Opening of Pandora's Box?. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1767-1769.	4.4	4
520	Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way?. <i>Gastroenterology</i> , 2015, 149, 1121-1123.	1.3	4
521	Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal. <i>Digestive and Liver Disease</i> , 2017, 49, 864-871.	0.9	4
522	PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 623-629.	4.1	4

#	ARTICLE	IF	CITATIONS
523	DOP49 Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S056-S057.	1.3	4
524	Detection and management of early stage inflammatory bowel disease: an update for clinicians. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 547-555.	3.0	4
525	634â€ŒTransitioning From Vedolizumab IV to Vedolizumab SC in Patients With Ulcerative Colitis: Results From the VISIBLE Program. <i>American Journal of Gastroenterology</i> , 2019, 114, S369-S370.	0.4	4
526	Endoscopy after surgery in inflammatory bowel disease: Crohnâ€™s disease recurrence and pouch surveillance. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 829-841.	3.0	4
527	Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures. <i>American Journal of Gastroenterology</i> , 2020, 115, 1719-1721.	0.4	4
528	DOP13 Clinical and endoscopic response to ustekinumab in Crohnâ€™s disease: Week 16 interim analysis of the STARDUST trial. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S049-S052.	1.3	4
529	IBD goes home: from telemedicine to self-administered advanced therapies. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 17-29.	3.1	4
530	Is It Crohnâ€™s Disease?. <i>Gastroenterology</i> , 2020, 159, 1244-1246.	1.3	4
531	Golimumab: Clinical update on its use for ulcerative colitis. <i>Drugs of Today</i> , 2015, 51, 171.	1.1	4
532	Endoscopic and Clinical Efficacy Demonstrated With Oral Ozanimod in Moderately to Severely Active Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, S371.	0.4	4
533	Anti-fibrotic Drugs for Crohnâ€™s Disease: Ready for Prime Time?. <i>Current Pharmaceutical Design</i> , 2019, 25, 47-56.	1.9	4
534	Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. <i>Journal of Clinical Medicine</i> , 2021, 10, 5642.	2.4	4
535	Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2059-2073.e7.	4.4	4
536	Do JAK inhibitors have a realistic future in treating Crohnâ€™s disease?. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 181-183.	3.0	4
537	The Role of Magnetic Resonance Imaging in Detecting Intestinal Fibrosis in Crohnâ€™s Disease. <i>Current Drug Targets</i> , 2012, 13, 1273-1279.	2.1	3
538	Regulatory T-Cell Therapy for Crohn's Disease: In Vivo Veritas. <i>Gastroenterology</i> , 2012, 143, 1135-1138.	1.3	3
539	Editorial (Thematic Issue: New Mechanisms and Targets for IBD Therapy: Translational) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 10	2.1	3
540	P303 Ulcerative colitis (UC) in the elderly â€“ Moderate at onset but then a milder course? An IG-IBD study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S190-S191.	1.3	3

#	ARTICLE	IF	CITATIONS
541	DOP078 Are IBD specialists aware of biosimilar monoclonal antibodies? Results from a survey among ECCO members. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S53.	1.3	3
542	Efficacy and Safety of Oral Tofacitinib as Maintenance Therapy in Patients with Moderate to Severe Ulcerative Colitis: Results from a Phase 3 Randomized Controlled Trial. <i>Gastroenterology</i> , 2017, 152, S199.	1.3	3
543	Authors'™ Reply to Pires et al.: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes". <i>Drugs</i> , 2018, 78, 853-855.	10.9	3
544	Evolving strategies and goals of treatment in ulcerative colitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 1-2.	2.4	3
545	Biologic therapies in ulcerative colitis: primi inter pares?. <i>Current Drug Targets</i> , 2018, 19, 748-756.	2.1	3
546	P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate-to-severe ulcerative colitis: UNIFI. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S256-S257.	1.3	3
547	Novel Targets for Therapeutic Intervention in Inflammatory Bowel Disease: Research Drives Clinic. <i>Current Pharmaceutical Design</i> , 2019, 25, 5-6.	1.9	3
548	Timely Use of Biologics in Early Crohn's™ Disease: The Return of "Hit Hard and Early". <i>Digestive Diseases and Sciences</i> , 2019, 64, 3035-3037.	2.3	3
549	P036 LONG-TERM SAFETY AND EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II). <i>Inflammatory Bowel Diseases</i> , 2019, 25, S18-S18.	1.9	3
550	New Drugs in the Ulcerative Colitis Pipeline: Prometheus Unbound. <i>Gastroenterology</i> , 2020, 158, 467-470.	1.3	3
551	Predictors for short bowel syndrome in Crohn's disease. <i>Digestive and Liver Disease</i> , 2020, 52, 1455-1460.	0.9	3
552	COVID-19 and gastrointestinal symptoms: the dust has not settled yet. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 877-878.	3.0	3
553	An Unusual Case of Cardiac Involvement in Crohn's™ Disease. <i>Gastroenterology</i> , 2021, 161, 431-433.	1.3	3
554	Efficacy and Safety of Ustekinumab as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFI. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, .	0.5	3
555	COVID-19 and digestive health. <i>United European Gastroenterology Journal</i> , 2020, 8, 624-626.	3.8	3
556	Onset of Efficacy of Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Multinational, Phase 3 Clinical Trials. <i>American Journal of Gastroenterology</i> , 2016, 111, S260-S261.	0.4	3
557	Iron Deficiency: The Hidden Miscreant in Inflammatory Bowel Disease. <i>Current Drug Targets</i> , 2014, 15, 1011-1019.	2.1	3
558	Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient Profile. <i>Current Drug Targets</i> , 2019, 20, 1327-1338.	2.1	3



#	ARTICLE	IF	CITATIONS
559	â€˜Treat to Targetâ€™™ in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy. <i>Current Drug Targets</i> , 2020, 22, 117-125.	2.1	3
560	Evolving Treatment Algorithms in Crohn's Disease. <i>Current Drug Targets</i> , 2018, 19, 782-790.	2.1	3
561	Efficacy of a New Nutraceutical Formulation in Patients with Symptomatic Uncomplicated Diverticular Disease (SUDD): a Prospective Observational Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 49-52.	0.9	3
562	S0653â€ŒLong-Term Treatment With Vedolizumab SC in Ulcerative Colitis: Interim Results From VISIBLE OLE. <i>American Journal of Gastroenterology</i> , 2020, 115, S327-S327.	0.4	3
563	Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 265-272.	3.7	3
564	Artificial Endoscopy and Inflammatory Bowel Disease: Welcome to the Future. <i>Journal of Clinical Medicine</i> , 2022, 11, 569.	2.4	3
565	OP07 Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: A post-hoc analysis from the SELECTION trial. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i007-i008.	1.3	3
566	Cross-Sectional Imaging Instead of Colonoscopy in Inflammatory Bowel Diseases: Lights and Shadows. <i>Journal of Clinical Medicine</i> , 2022, 11, 353.	2.4	3
567	Faecal incontinence in inflammatory bowel disease: The Nancy experience. <i>Digestive and Liver Disease</i> , 2022, 54, 1195-1201.	0.9	3
568	Evolution and New Horizons of Endoscopy in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2022, 11, 872.	2.4	3
569	Confounding and bias in observational studies in inflammatory bowel disease: a metaâ€Œepidemiological study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 712-721.	3.7	3
570	Commentary: antibodies reacting with the infliximab Fab portion - something new?. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 552-552.	3.7	2
571	P511 Does the location of an IBD centre impact the rates of early postoperative endoscopic recurrence after ileocecal resection in Crohn's disease? Results from the MULTIPER database. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S281.	1.3	2
572	Reduced cortical thickness in patients with acute-on-chronic liver failure due to non-alcoholic etiology. <i>Journal of Translational Medicine</i> , 2015, 13, 322.	4.4	2
573	Predicting future disease course in Crohnâ€™s disease by colonoscopy or magnetic resonance: which is the crystal ball?. <i>Gut</i> , 2015, 64, 1347-1348.	12.1	2
574	Editorial: CCR7 is required for leukocyte egression in an experimental model of Crohn's disease-like ileitis. <i>Journal of Leukocyte Biology</i> , 2015, 97, 1000-1002.	3.3	2
575	Is Mesalamine Effective for the Induction of Remission in Crohn's Disease?. <i>Inflammatory Bowel Diseases</i> , 2017, 23, E22-E23.	1.9	2
576	Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 767-768.	1.3	2

#	ARTICLE	IF	CITATIONS
577	A Prolonged Follow-Up on the Efficacy and Safety of Infliximab Biosimilar CT-P13 in IBD Across Italy: The Prosit Cohort. <i>Gastroenterology</i> , 2017, 152, S108.	1.3	2
578	Telehealth in Inflammatory Bowel Disease: Every Patient May Need a Coach!. <i>Gastroenterology</i> , 2018, 154, 1196-1198.	1.3	2
579	DOP51 Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S058-S059.	1.3	2
580	Effectiveness of Infliximab Biosimilar in Crohn's Disease: A Dime, A Dozen. <i>Gastroenterology</i> , 2019, 156, 2349-2351.	1.3	2
581	Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. <i>Immunotherapy</i> , 2019, 11, 565-575.	2.0	2
582	P681 Ustekinumab therapy induced clinically meaningful improvement and remission as measured by the Inflammatory Bowel Disease Questionnaire: Results from the phase 3 UNIFI induction and maintenance studies. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S460-S460.	1.3	2
583	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 3057-3058.	4.4	2
584	Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 997-998.	3.7	2
585	Improving quality of care in endoscopy of inflammatory bowel disease: can we do better?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 819-828.	3.0	2
586	P448 Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extension. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S403-S403.	1.3	2
587	JAK or GUT Selectivity: Tipping the Balance for Efficacy and Safety in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1185-1187.	1.3	2
588	Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic. <i>Gastroenterology</i> , 2021, 160, 472-473.	1.3	2
589	Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab. <i>BioDrugs</i> , 2021, 35, 35-45.	4.6	2
590	The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases. <i>Crohn's &amp; Colitis</i> 360, 2021, 3, .	1.1	2
591	P271 Evolving Targets in Ulcerative colitis: Defining Disease Clearance in the VARSITY Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S305-S305.	1.3	2
592	Protecting patients with IBD during the COVID-19 pandemic. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 639.	8.1	2
593	P565 Efficacy and safety of long-term treatment with ustekinumab in moderate-to-severe ulcerative colitis patients with delayed response to ustekinumab induction: Results from UNIFI 2-year long-term extension. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S476-S477.	1.3	2
594	Long-Term Safety in the Open-Label Period of a Phase 2a Study of Brazikumab, an Antibody Against Interleukin-23. <i>American Journal of Gastroenterology</i> , 2018, 113, S339.	0.4	2

#	ARTICLE	IF	CITATIONS
595	832â€fPharmacokinetics and Exposure-Response Relationships of Ustekinumab in Patients With Ulcerative Colitis: Results From the UNIFI Induction and Maintenance Studies. <i>American Journal of Gastroenterology</i> , 2019, 114, S481-S482.	0.4	2
596	Anti-adhesion Molecules in IBD: Does Gut Selectivity Really Make the Difference?. <i>Current Pharmaceutical Design</i> , 2019, 25, 19-24.	1.9	2
597	Tofacitinib Inhibits Leukocyte Trafficking Across the Intestinal Endothelial Barrier in a Specific Cohort of Ulcerative Colitis Patients. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 971-976.	1.9	2
598	DOP37 Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i085-i087.	1.3	2
599	JAK inhibitors in crohnâ€™s disease: ready to go?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 145-161.	4.1	2
600	Editorial: [Hot Topic: Imaging Inflammatory Bowel Disease: Looking Beyond the Mucosa]. <i>Current Drug Targets</i> , 2012, 13, 1223-1223.	2.1	1
601	Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 277-278.	3.7	1
602	Leukoapheresis in Crohn's disease: the final curtain?. <i>Gut</i> , 2013, 62, 487-488.	12.1	1
603	Introduction. <i>Digestive Diseases</i> , 2014, 32, 1-1.	1.9	1
604	Commentary: adjunct antibiotic combination therapy for ulcerative colitis â€“ is it time to investigate <i>usobacterium varium</i> ? <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1333-1333.	3.7	1
605	P067 IBD98E promotes mucosal wound healing through epithelial cell proliferation in DSS-induced colitis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S90-S91.	1.3	1
606	DOP098 The risk of postoperative complications following preoperative immunosuppressive therapy in patients undergoing ileocolonic resection for Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S62.	1.3	1
607	DOP028 Development of red flags for early referral of adults with symptoms and signs suggestive of Crohn's disease: an IOIBD initiative. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S28.	1.3	1
608	DOP036 LÃ©mann Index assessment over time in Crohn's disease patients treated with anti TNFs: a pilot observational cohort study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S32.	1.3	1
609	P362 Retrospective comparison of the efficacy of anti-TNF agents in isolation or combined with azathioprine in prevention of early postoperative endoscopic recurrence in Crohn's disease from the MULTIPER database. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S216.	1.3	1
610	Tu1955 Fecal Calprotectin Reductions in Patients With Mucosal Healing During Vedolizumab Induction Therapy in GEMINI 1. <i>Gastroenterology</i> , 2016, 150, S989.	1.3	1
611	Drug Development for Inflammatory Bowel Disease: Interaction Among Academia, Industry and Regulatory Authorities. <i>Journal of Crohn's and Colitis</i> , 2016, 10, S541-S541.	1.3	1
612	The Crohn's Diseaseâ€™Ulcerative Colitis Clinical Appraisal. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 638-639.	4.4	1

#	ARTICLE	IF	CITATIONS
613	CX601, Allogeneic Expanded Adipose-Derived Mesenchymal Stem Cells (EASC), for Complex Perianal Fistulas in Crohn's Disease: Long-Term Results from a Phase III Randomized Controlled Trial. <i>Gastroenterology</i> , 2017, 152, S187.	1.3	1
614	Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach. <i>Digestive Diseases</i> , 2018, 36, 346-353.	1.9	1
615	Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1257-1258.	1.3	1
616	P258 Abdominal pain and its relationship with clinical outcomes, biomarker levels, and health-related quality of life in patients with moderate to severe ulcerative colitis: data from U-ACHIEVE, a Phase 2b study of upadacitinib. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S226-S226.	1.3	1
617	P311 Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with ulcerative colitis: Results from the UNIFI induction study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S255-S256.	1.3	1
618	Tu1740 " Sustained Remission in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 Unifi Maintenance Study. <i>Gastroenterology</i> , 2019, 156, S-1106-S-1107.	1.3	1
619	DOP47 Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S054-S055.	1.3	1
620	P.02.12 PREDICTIVE VALUE OF THE "DICA" ENDOSCOPIC CLASSIFICATION ON THE OUTCOME OF DIVERTICULAR DISEASE OF THE COLON: A 1-YEAR ANALYSIS FROM THE INTERNATIONAL, MULTICENTER, PROSPECTIVE STUDY. <i>Digestive and Liver Disease</i> , 2019, 51, e152-e153.	0.9	1
621	Psychological Functioning of Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e112-e112.	1.9	1
622	OP33 BUB1: a new player in the development of Crohn's disease (CD)-associated fibrosis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S612-S612.	1.3	1
623	P376 Effects of IV vedolizumab on health-related quality of life and work productivity in patients with Crohn's disease: results from the Phase 3b VERSIFY trial. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S293-S294.	1.3	1
624	OTH-12...Efficacy and safety of vedolizumab subcutaneous formulation for ulcerative colitis: results of the visible trial. , 2019, , .		1
625	215 "Efficacy and Safety of Upadacitinib as an Induction Therapy for Patients With Moderately-to-Severely Active Ulcerative Colitis: Combined Results From 382 Subjects in the Phase 2b Study U-ACHIEVE. <i>American Journal of Gastroenterology</i> , 2019, 114, S131-S131.	0.4	1
626	772"Long-Term Mucosal Healing, Clinical Response and Clinical Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From the Open-Label Extension Study TURANDOT II. <i>American Journal of Gastroenterology</i> , 2019, 114, S448-S449.	0.4	1
627	All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 51-53.	4.4	1
628	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 3055.	4.4	1
629	Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials. <i>Journal of Clinical Medicine</i> , 2020, 9, 2350.	2.4	1
630	Author response to: Covid-19-related pancreatic injury. <i>British Journal of Surgery</i> , 2020, 107, e191-e191.	0.3	1

#	ARTICLE	IF	CITATIONS
631	Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1209-1210.	3.7	1
632	DOP12 Efficacy of ustekinumab for ulcerative colitis through 2 years: Results of the UNIFI maintenance study and long-term extension. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S049-S049.	1.3	1
633	New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases. <i>Current Drug Targets</i> , 2021, 22, 370-378.	2.1	1
634	P383 Relationship between histo-endoscopic mucosal healing and baseline characteristics in patients with moderately to severely active Ulcerative Colitis receiving filgotinib in the phase 2b/3 SELECTION study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S395-S396.	1.3	1
635	Adalimumab biosimilar in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 775-776.	8.1	1
636	Bispecific antibodies for the treatment in inflammatory bowel disease: an avenue worth exploring?. <i>Expert Opinion on Biological Therapy</i> , 2021, , 1-3.	3.1	1
637	Endoscopic Surveillance in Inflammatory Bowel Disease: The VIRTUE Is in High Definition. <i>Gastroenterology</i> , 2022, 162, 988-990.	1.3	1
638	Comparison of two methods for the in-vivo diagnosis of <i>Helicobacter pylori</i> infection using a tablet of 13C-urea. <i>Minerva Gastroenterology</i> , 2017, 63, 319-326.	0.5	1
639	A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn's Disease; Data From CALM 2017 ACG Governors Award for Excellence in Clinical Research. <i>American Journal of Gastroenterology</i> , 2017, 112, S321.	0.4	1
640	P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i379-i380.	1.3	1
641	DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i132-i134.	1.3	1
642	Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Diseases: Chromoendoscopy or Non-Chromoendoscopy, That Is the Question. <i>Journal of Clinical Medicine</i> , 2022, 11, 509.	2.4	1
643	DOP80 Integrated tissue transcriptomic and serum proteomic interrogation reveals biomarkers for endoscopic improvement and histologic remission after JAK3/TEC inhibition in Ulcerative Colitis (UC) (Phase 2b Vibrato study). <i>Journal of Crohn's and Colitis</i> , 2022, 16, i124-i124.	1.3	1
644	P230 Ultrasonography-based and Magnetic Resonance-based LÃ©mann Index: two sides of the same coin. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i278-i279.	1.3	1
645	OP19 Classifying perianal fistulising Crohn's Disease: An expert-consensus to guide decision-making in daily practice and clinical trials. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i021-i022.	1.3	1
646	Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1206-1207.	3.7	1
647	Composite outcomes in observational studies of Crohn's disease: a systematic review and meta-analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210927.	3.2	1
648	High prevalence of SARS-Coronavirus-2 in patients with inflammatory bowel disease and the role of soluble angiotensin converting Enzyme2. <i>Archives of Physiology and Biochemistry</i> , 0, , 1-8.	2.1	1

#	ARTICLE	IF	CITATIONS
649	Letter: pancreatic involvement in inflammatory bowel disease—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 371-371.	3.7	1
650	Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases. <i>International Journal of Colorectal Disease</i> , 2013, 28, 1281-1286.	2.2	0
651	Vedolizumab Induces Clinical Response and Remission Across a Range of Baseline Fecal Calprotectin Levels in Patients with Ulcerative Colitis: Results from GEMINI 1. <i>American Journal of Gastroenterology</i> , 2014, 109, S486.	0.4	0
652	Editorial (Thematic Issue: Medical Challenges in Inflammatory Bowel Disease: Quo Vadis in Disease) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	2.1	0
653	P547 Biological agents for moderately-to-severely active ulcerative colitis in adults: a network meta-analysis of randomized controlled trials. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S296.	1.3	0
654	DOP002 Conditional deletion of Prep1 in the intestinal epithelium alters epithelial homeostasis, intestinal development, and controls colitis susceptibility. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S15-S16.	1.3	0
655	P020 Silencing of prolyl hydroxylase 1 in intestinal microvascular endothelial cells prevents inflammation-induced endothelial dysfunction and dampens murine colitis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S72.	1.3	0
656	Editorial: long-term safety and efficacy of certolizumab pegol for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1243-1243.	3.7	0
657	P519 Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocecal resection for Crohn's disease: results from the MULTIPER database. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S284.	1.3	0
658	DOP008 The absence of the Triggering Receptor Expressed on Myeloid Cells type-2 (TREM-2) induces a transmissible and protective intestinal microbiota for colitis and colitis associated cancer. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S18.	1.3	0
659	P015 The VEGFC/VEGFR3 pathway controls colitis associated cancer formation and progression through lymphangiogenesis and lymphatic endothelial VE-cadherin. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S70-S71.	1.3	0
660	DOP082 Identified areas of need to enhance evidence-based inflammatory bowel disease management and patient care. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S54-S55.	1.3	0
661	PTU-072—Discontinuation of Infliximab in Patients with Ulcerative Colitis is Associated with Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Gut</i> , 2016, 65, A88-A89.	12.1	0
662	19 Infliximab Discontinuation Is Associated With a Higher Risk for Relapse in Patients With Ulcerative Colitis in Remission: A Multinational Collaborative Retrospective Study. <i>Gastroenterology</i> , 2016, 150, S6.	1.3	0
663	Sa1836 Stimulation of the $\omega$ -3 Docosahexaenoic Acid (DHA) Metabolism via MFSD2A as a Novel Therapy for Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016, 150, S377.	1.3	0
664	Su1835 Impact of Tumour Necrosis Factor Antagonists on Avoiding Surgery in Stricturing Crohn's Disease: A Tertiary Center Real-Life Experience. <i>Gastroenterology</i> , 2016, 150, S566.	1.3	0
665	Mo1090 The Costs of Care for Patients With Ulcerative Colitis: Effect of Adalimumab on Health Care Resources Utilisation in Clinical Practice From INSPIRADA. <i>Gastroenterology</i> , 2016, 150, S631.	1.3	0
666	PC.01.2 PREDICTIVE VALUE OF THE "DICA" ENDOSCOPIC CLASSIFICATION ON THE OUTCOME OF THE DIVERTICULAR DISEASE OF THE COLON: AN INTERNATIONAL STUDY. <i>Digestive and Liver Disease</i> , 2016, 48, e68.	0.9	0

#	ARTICLE	IF	CITATIONS
667	Sa1075 Safety of Sodium Picosulphate-Based Bowel Preparation: A Meta-Analysis.. Gastrointestinal Endoscopy, 2016, 83, AB226.	1.0	0
668	Sa1408 Predictive Value of the "DICA" Endoscopic Classification on the Outcome of Diverticular Disease of the Colon: An International Study. Gastroenterology, 2016, 150, S307.	1.3	0
669	852 Cx601, Expanded Allogeneic Adipose-Derived Mesenchymal Stem Cells (eASC), for Complex Perianal Fistulas in Crohn's Disease: Results From a Phase III Randomized Controlled Trial. Gastroenterology, 2016, 150, S181.	1.3	0
670	Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel. Gastroenterology, 2016, 150, S991.	1.3	0
671	Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer" authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1554-1555.	3.7	0
672	Effect of Adalimumab dose Escalation on Clinical, Health-Related Quality of Life, Treatment Satisfaction and Work Productivity Outcomes Among Patients with Ulcerative Colitis in a Clinical Practice Setting: Results from Inspirada. Gastroenterology, 2017, 152, S742-S743.	1.3	0
673	Rapid Detection of Anti-Infliximab Antibodies in Inflammatory Bowel Disease Patients Treated with the Reference Biologic or the Biosimilar CT-P13: Performance Comparison with Elisa. Gastroenterology, 2017, 152, S384.	1.3	0
674	Switching from Infliximab Originator to CT-P13 is not Related to Increased Immunogenicity in IBD Patients: A Prospective Case-Control Study. Gastroenterology, 2017, 152, S384.	1.3	0
675	Effect of Adalimumab on Extraintestinal Manifestations Among Patients with Ulcerative Colitis in a Clinical Practice Setting: Results from Inspirada. Gastroenterology, 2017, 152, S743.	1.3	0
676	Presentation and Surgical Interventions for Crohn's Disease with Perianal Fistula in the Biologics Era: Results from a Multicentre Study. Gastroenterology, 2017, 152, S1282.	1.3	0
677	Antibodies to Infliximab in Patients Treated with Either the Reference Biologic or the Biosimilar CT-P13 Show Identical Reactivity Towards Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S386.	1.3	0
678	Multicentre Cohort Study to Evaluate the Need for Re-Intervention following Multimodal Treatment in Crohn's Disease with Perianal Fistula. Gastroenterology, 2017, 152, S778.	1.3	0
679	Comparative Accuracy of us Versus MRI and Colonoscopy in Assessing Disease Activity and Complications and Influencing the Decision-Making Process in Crohn's Disease. Gastroenterology, 2017, 152, S66.	1.3	0
680	Stimulation of CYP450-Mediated $\omega$ -3 Docosahexaenoic Acid (DHA) Metabolism via MFSD2A as a Novel Therapy for Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S188.	1.3	0
681	Centrally-Determined Standardization of Flow Cytometry Methods Reduces Inter-Laboratory Variation in a Prospective Multicenter Study. Gastroenterology, 2017, 152, S772.	1.3	0
682	Illness Perception in IBD Patients: A Prospective Study. Gastroenterology, 2017, 152, S800.	1.3	0
683	Sphingosine-1-Phosphate Receptor 3 Orchestrates Epithelial-Mesenchymal Transition Promoting Intestinal Fibrosis in CD Patients. Gastroenterology, 2017, 152, S994.	1.3	0
684	Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough?. Digestive Diseases and Sciences, 2017, 62, 2964-2965.	2.3	0

#	ARTICLE	IF	CITATIONS
685	OC.06.1: Onset of Efficacy of Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in two Multinational, Phase 3 Clinical Trials. <i>Digestive and Liver Disease</i> , 2017, 49, e90-e91.	0.9	0
686	AODWE-008...Multicentre ecco collaborative group study to evaluate the need for re-intervention following multimodal treatment in crohn's disease with perianal fistula. , 2017, , .		0
687	PWE-033...Presentation and surgical interventions for crohn's disease with perianal fistula in the biologics era: results from a multicentre study. , 2017, , .		0
688	P004 Stimulation of CYP450-mediated $\gamma$ -3 docosahexaenoic acid metabolism via MFSD2A as a novel therapy for inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S81-S81.	1.3	0
689	Editorial: antigenic response to CTCP13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 575-576.	3.7	0
690	Editorial Personalized Medicine in Inflammatory Bowel Diseases: Myth or Reality?. <i>Current Drug Targets</i> , 2018, 19, 721-721.	2.1	0
691	P406 General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S311-S312.	1.3	0
692	Medico-surgical Management: A Solid Therapeutic Pillar for Improved Patients' Outcomes in Inflammatory Bowel Diseases. <i>Current Drug Targets</i> , 2019, 20, 1315-1316.	2.1	0
693	Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind the Gap?. <i>Current Medicinal Chemistry</i> , 2019, 26, 246-247.	2.4	0
694	P036 LONG-TERM SAFETY AND EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II). <i>Gastroenterology</i> , 2019, 156, S25-S26.	1.3	0
695	P477 Clinical remission by legacy vs. FDA definitions: definition justification and results from UNIFI Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S350-S351.	1.3	0
696	P029 Serum bile acids profiling in IBD patients treated with anti-TNFs. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S100-S101.	1.3	0
697	P499 Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn's disease: results from VISIBLE 1 and 2. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S361-S362.	1.3	0
698	715...Corticosteroid Sparing Effects of Ustekinumab Therapy in UC Patients: Results From the UNIFI Program. <i>American Journal of Gastroenterology</i> , 2019, 114, S421-S421.	0.4	0
699	PTH-077...De-escalating therapy in patients with crohn's disease receiving adalimumab: subgroup analysis of the calm study. , 2019, , .		0
700	PTH-091...Effects of vedolizumab on HRQoL and work productivity in Crohn's disease: results from versify. , 2019, , .		0
701	689...Early Improvement After Intravenous Ustekinumab Induction in Patients With Ulcerative Colitis: Results From the UNIFI Induction Trial. <i>American Journal of Gastroenterology</i> , 2019, 114, S404-S404.	0.4	0
702	842...Impact of Response and Inflammatory Burden at Start of Maintenance Therapy on Clinical Efficacy of Ustekinumab Dosing Regimen in UC: Week 44 Results From UNIFI. <i>American Journal of Gastroenterology</i> , 2019, 114, S487-S488.	0.4	0



#	ARTICLE	IF	CITATIONS
703	757â€fHistologic Improvement With Vedolizumab vs. Adalimumab in Ulcerative Colitis: Results From VARSITY. American Journal of Gastroenterology, 2019, 114, S442-S442.	0.4	0
704	697â€fSafety of Ustekinumab in Inflammatory Bowel Diseases: Integrated Safety Analysis of Results From Phase 2 and 3 Studies in Crohn's Disease and Ulcerative Colitis. American Journal of Gastroenterology, 2019, 114, S408-S409.	0.4	0
705	P380 A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMXÂ® for mild-to-moderate ulcerative colitis. Journal of Crohn's and Colitis, 2019, 13, S296-S297.	1.3	0
706	644â€fIncidence of Venous Thromboembolic Events in Patients With Ulcerative Colitis Treated With Tofacitinib in the Ulcerative Colitis Clinical Development Program. American Journal of Gastroenterology, 2019, 114, S377-S377.	0.4	0
707	Reply. Gastroenterology, 2020, 158, 1177-1178.	1.3	0
708	Reply. Gastroenterology, 2021, 160, 2223-2224.	1.3	0
709	DOP84 Early treatment responses within 14 days of intravenous vedolizumab induction therapy for Crohnâ€™s Disease: Post hoc analysis of patient-reported outcomes from the VISIBLE 2 study. Journal of Crohn's and Colitis, 2021, 15, S115-S116.	1.3	0
710	Reply. Clinical Gastroenterology and Hepatology, 2022, 20, e346.	4.4	0
711	Cluster Randomized Trials: Lessons for Inflammatory Bowel Disease Trials. Journal of Crohn's and Colitis, 2021, , .	1.3	0
712	Vedolizumab Results in Durable Clinical Remission in Crohnâ€™s Disease. American Journal of Gastroenterology, 2014, 109, S476-S477.	0.4	0
713	Symptomatic Improvement Within 3 Days With Tofacitinib Induction Therapy in Patients With Ulcerative Colitis: Results From OCTAVE Induction 1 and 2. American Journal of Gastroenterology, 2017, 112, S331.	0.4	0
714	Long-Term Safety of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Antibody SHP647 in Ulcerative Colitis: An Open-Label Extension Study (TURANDOT II). American Journal of Gastroenterology, 2018, 113, S347.	0.4	0
715	Sustained Remission in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 UNIFI Maintenance Study. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
716	817â€fIdentification of Biomarkers and Mechanistic Insight for Upadacitinib in Crohnâ€™s Disease: Serum Inflammatory Mediator Analysis From the Phase 2b CELEST Study. American Journal of Gastroenterology, 2019, 114, S471-S471.	0.4	0
717	Efficacy and Safety of Filgotinib as Maintenance Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
718	Carcinomas in inflammatory bowel disease: a narrative review on diagnostic imaging techniques. Chinese Clinical Oncology, 2021, .	1.2	0
719	Editorial: an accurate, reliable and responsive ultrasound activity score for Crohnâ€™s disease? Sounds good to US. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 362-363.	3.7	0
720	Surgery versus Medical Therapy in Luminal Ileocecal Crohn's Disease. Clinics in Colon and Rectal Surgery, 2022, 35, 072-077.	1.1	0

#	ARTICLE	IF	CITATIONS
721	P457 Long-term cumulative safety of ustekinumab in bionative patients with Crohn's Disease and Ulcerative Colitis. Journal of Crohn's and Colitis, 2022, 16, i434-i435.	1.3	0
722	P267 Milan Ultrasound Criteria are accurate in assessing endoscopic remission and treatment response in patients with ulcerative colitis. Journal of Crohn's and Colitis, 2022, 16, i306-i307.	1.3	0
723	Novel approach to endoscopic submucosal dissection using an additional working channel: a case report. Endoscopy, 2022, , .	1.8	0
724	Systematic Literature Review and Meta-analysis: Real-World Mucosal Healing in Vedolizumab-Treated Patients with Crohn's Disease. GastroHep, 2022, 2022, 1-12.	0.6	0
725	Editorial: protecting hypoxia-inducible factor 1a and gut integrity with <sc>GB</sc> 004" a promising therapeutic approach for ulcerative colitis? Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 735-736.	3.7	0
726	Editorial: vedolizumab in inflammatory bowel diseases"less is more? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 445-446.	3.7	0
727	Long-Term Outcomes of the Excluded Rectum in Crohn's Disease: A Multicenter International Study. Inflammatory Bowel Diseases, 2022, , .	1.9	0